Antion Biosciences, based in Geneva, is at the forefront of cell and gene therapy with its latest breakthrough. They're pioneering the development of next-generation anti-CD19 chimeric antigen receptor (CAR) T-cells tailored for B-cell driven autoimmune diseases.

Autoimmune conditions affect up to 10% of the global population, posing a significant economic burden estimated at over US $120 billion annually. Recent advancements suggest that targeted CAR T-cell therapy holds tremendous promise for severe autoimmune cases. According to renowned expert Prof. Dr. Georg Schett, recognized as one of Time Magazine's Most Influential People in Health, the results are remarkable: "Patients not only achieve drug-free remission, but many could be considered cured of their autoimmune ailment." This has attracted attention from various quarters, including industry giants like Novartis, keen to explore this burgeoning field.

Antion, sees this as a pivotal moment, heralding a paradigm shift in autoimmune disease management and offering unprecedented avenues for life-changing therapies for millions worldwide. "Our strategy is to anticipate future needs and craft a product that will endure the test of time."

Antion's "miCAR19" represents a breakthrough in engineered therapeutics, addressing critical limitations of current developmental products. Foremost among its advantages is its focus on patient safety. Traditional CAR T-cell therapies in oncology necessitate chemotherapeutic pre-conditioning, a measure often deemed undesirable, if not unacceptable, for autoimmune patients. Antion's safety-optimized product is genetically engineered to obviate the need for pre-conditioning while mitigating the risk of hyperinflammation. As an allogeneic product, it not only offers off-the-shelf availability but also streamlines manufacturing to meet the burgeoning global demand for this potentially curative therapy.

"This marks the dawn of a new era for Antion. Our technology platform has proven its mettle in our hands and those of our partners, instilling confidence in our ability to develop a robust product. Accelerating its progression to clinical trials is our foremost objective," emphasized Dr. Alessandrini.

 

Source: globenewswire.com

Report Abuse